{"prompt": "['Official Protocol Title:', 'A Phase 3, randomized, double-blind trial of pembrolizumab', '(MK-3475) with or without lenvatinib (E7080/MK-7902) in', 'participants with treatment-na\u00efve, metastatic nonsmall cell lung', 'cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'NCT number:', 'NCT03829332', 'Document Date:', '15-Sep-2021']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '1', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Title Page', 'THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING', 'TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK', 'SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A.', '(MSD).', 'Protocol Title: A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475)', 'with or without lenvatinib (E7080/MK-7902) in participants with treatment-na\u00efve, metastatic', 'nonsmall cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'Protocol Number: 007-06 (E7080-G000-314)', 'Compound Number: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', 'Sponsor Name:', 'Merk Sharp & Dohme Corp., a subsidiary of Merk & Co., Inc.', '(hereafter referred to as the Sponsor or MSD)', 'The study is co-funded by MSD and Eisai.', 'Legal Registered Address:', 'One Merk Drive', 'P.O. Box 100', 'Whitehouse Station, New Jersey, 08889-0100, U.S.A.', 'Regulatory Agency Identifying Number(s):', 'IND', '140221', 'EudraCT', '2018-003794-98', 'Approval Date: 15 September 2021', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '2', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Sponsor Signatory', 'Typed Name:', 'Date', 'Title:', 'Protocol-specific Sponsor contact information can be found in the Investigator Study', 'File Binder (or equivalent).', 'Investigator Signatory', 'I agree to conduct this clinical study in accordance with the design outlined in this protocol', 'and to abide by all provisions of this protocol.', 'Typed Name:', 'Date', 'Title:', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}